Teladoc Health (NYSE:TDOC) had its target price raised by equities researchers at Royal Bank of Canada from $200.00 to $235.00 in a research report issued on Thursday, BenzingaRatingsTable reports. The firm presently has an “outperform” rating on the health services provider’s stock. Royal Bank of Canada’s target price suggests a potential downside of 1.11% from the stock’s previous close.
Several other analysts have also recently commented on the company. JPMorgan Chase & Co. increased their target price on Teladoc Health from $194.00 to $240.00 and gave the stock an “overweight” rating in a report on Wednesday, July 15th. Stephens initiated coverage on Teladoc Health in a report on Monday, July 6th. They set an “overweight” rating and a $250.00 target price on the stock. SVB Leerink increased their target price on Teladoc Health from $197.00 to $227.00 and gave the stock an “outperform” rating in a report on Monday, July 6th. Deutsche Bank raised their price target on Teladoc Health from $184.00 to $238.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wells Fargo & Co raised their price target on Teladoc Health from $105.00 to $135.00 and gave the company an “equal weight” rating in a report on Thursday, April 16th. Fifteen research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $195.04.
Shares of Teladoc Health stock opened at $237.63 on Thursday. The company has a quick ratio of 6.14, a current ratio of 6.14 and a debt-to-equity ratio of 0.45. The stock has a 50 day moving average price of $207.13 and a two-hundred day moving average price of $158.76. Teladoc Health has a 12-month low of $54.58 and a 12-month high of $240.00.
In related news, Director William H. Frist sold 370 shares of Teladoc Health stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $180.00, for a total value of $66,600.00. Following the sale, the director now owns 5,788 shares of the company’s stock, valued at approximately $1,041,840. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO David William Sides sold 3,117 shares of Teladoc Health stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $216.67, for a total value of $675,360.39. Following the completion of the sale, the chief operating officer now directly owns 7,299 shares in the company, valued at approximately $1,581,474.33. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 189,977 shares of company stock worth $36,248,032. 3.42% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Total Clarity Wealth Management Inc. purchased a new stake in shares of Teladoc Health in the fourth quarter worth $25,000. PrairieView Partners LLC bought a new stake in shares of Teladoc Health in the first quarter worth about $31,000. Pathstone Family Office LLC bought a new stake in Teladoc Health during the 1st quarter valued at approximately $31,000. Marshall Wace North America L.P. bought a new stake in Teladoc Health during the 1st quarter valued at approximately $35,000. Finally, Capital Advisory Group Advisory Services LLC bought a new stake in shares of Teladoc Health in the 1st quarter worth approximately $36,000. Institutional investors own 97.14% of the company’s stock.
About Teladoc Health
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Featured Article: What is systematic risk?
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.